Cover Image
Market Research Report

CTI BioPharma Corp. - Product Pipeline Review - 2015

Published by Global Markets Direct Product code 338088
Published Content info 56 Pages
Immediate Delivery Available
Price
Back to Top
CTI BioPharma Corp. - Product Pipeline Review - 2015
Published: July 22, 2015 Content info: 56 Pages
Description

Summary

Global Markets Direct's, 'CTI BioPharma Corp. - Product Pipeline Review - 2015', provides an overview of the CTI BioPharma Corp.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of CTI BioPharma Corp.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of CTI BioPharma Corp. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of CTI BioPharma Corp.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the CTI BioPharma Corp.'s pipeline products

Reasons to buy

  • Evaluate CTI BioPharma Corp.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of CTI BioPharma Corp. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the CTI BioPharma Corp.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of CTI BioPharma Corp. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of CTI BioPharma Corp.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of CTI BioPharma Corp. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues
Table of Contents
Product Code: GMDHC07292CDB

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • CTI BioPharma Corp. Snapshot
    • CTI BioPharma Corp. Overview
    • Key Information
    • Key Facts
  • CTI BioPharma Corp. - Research and Development Overview
    • Key Therapeutic Areas
  • CTI BioPharma Corp. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • CTI BioPharma Corp. - Pipeline Products Glance
    • CTI BioPharma Corp. - Late Stage Pipeline Products
      • Filing rejected/Withdrawn Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • CTI BioPharma Corp. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
  • CTI BioPharma Corp. - Drug Profiles
    • paclitaxel poliglumex
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pixantrone dimaleate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pacritinib
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lisofylline
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tosedostat
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • CTI BioPharma Corp. - Pipeline Analysis
    • CTI BioPharma Corp. - Pipeline Products by Target
    • CTI BioPharma Corp. - Pipeline Products by Route of Administration
    • CTI BioPharma Corp. - Pipeline Products by Molecule Type
    • CTI BioPharma Corp. - Pipeline Products by Mechanism of Action
  • CTI BioPharma Corp. - Recent Pipeline Updates
  • CTI BioPharma Corp. - Dormant Projects
  • CTI BioPharma Corp. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • CT-2584
      • nortopixantrone
      • topixantrone
  • CTI BioPharma Corp. - Company Statement
  • CTI BioPharma Corp. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • CTI BioPharma Corp., Key Information
  • CTI BioPharma Corp., Key Facts
  • CTI BioPharma Corp. - Pipeline by Indication, 2015
  • CTI BioPharma Corp. - Pipeline by Stage of Development, 2015
  • CTI BioPharma Corp. - Monotherapy Products in Pipeline, 2015
  • CTI BioPharma Corp. - Filing rejected/Withdrawn, 2015
  • CTI BioPharma Corp. - Phase III, 2015
  • CTI BioPharma Corp. - Phase II, 2015
  • CTI BioPharma Corp. - Phase I, 2015
  • CTI BioPharma Corp. - Pipeline by Target, 2015
  • CTI BioPharma Corp. - Pipeline by Route of Administration, 2015
  • CTI BioPharma Corp. - Pipeline by Molecule Type, 2015
  • CTI BioPharma Corp. - Pipeline Products by Mechanism of Action, 2015
  • CTI BioPharma Corp. - Recent Pipeline Updates, 2015
  • CTI BioPharma Corp. - Dormant Developmental Projects,2015
  • CTI BioPharma Corp. - Discontinued Pipeline Products, 2015
  • CTI BioPharma Corp., Subsidiaries

List of Figures

  • CTI BioPharma Corp. - Pipeline by Top 10 Indication, 2015
  • CTI BioPharma Corp. - Pipeline by Stage of Development, 2015
  • CTI BioPharma Corp. - Monotherapy Products in Pipeline, 2015
  • CTI BioPharma Corp. - Pipeline by Top 10 Target, 2015
  • CTI BioPharma Corp. - Pipeline by Top 10 Route of Administration, 2015
  • CTI BioPharma Corp. - Pipeline by Top 10 Molecule Type, 2015
  • CTI BioPharma Corp. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top